Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates

A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants, Journal of Biomedical Science

Omicron-specific booster may not be needed, U.S. monkey study finds

Novel self-amplifying RNA vaccine confers durable protection against COVID- 19, reduces viral shedding in primate study

Rational prediction of immunogenicity clustering through cross‐reactivity analysis of thirteen SARS‐CoV‐2 variants - Liang - 2024 - Journal of Medical Virology - Wiley Online Library

Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in nonhuman primates

Beta-spike-containing boosters induce robust and functional antibody responses to SARS-CoV-2 in macaques primed with distinct vaccines - ScienceDirect

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques - ScienceDirect

Vaccines, Free Full-Text

PDF) The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022